106 related articles for article (PubMed ID: 25326842)
21. Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects.
Haluzík M; Mráz M; Svačina Š
Drug Saf; 2014 Dec; 37(12):1003-10. PubMed ID: 25391858
[TBL] [Abstract][Full Text] [Related]
22. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
23. Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.
Semenya AM; Wilson SA
Am Fam Physician; 2020 Nov; 102(10):627-628. PubMed ID: 33179892
[No Abstract] [Full Text] [Related]
24. Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.
Kawanami D; Matoba K; Sango K; Utsunomiya K
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483245
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C
N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751
[No Abstract] [Full Text] [Related]
26. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
Jespersen MJ; Knop FK; Christensen M
Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):17-29. PubMed ID: 23094590
[TBL] [Abstract][Full Text] [Related]
27. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
29. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
[TBL] [Abstract][Full Text] [Related]
30. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
[TBL] [Abstract][Full Text] [Related]
32. [Incretin mimetic drugs: therapeutic positioning].
López Simarro F
Semergen; 2014 Jul; 40 Suppl 2():25-33. PubMed ID: 25311717
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials.
Caruso I; Cignarelli A; Giorgino F
Trends Endocrinol Metab; 2019 Sep; 30(9):578-589. PubMed ID: 31401015
[TBL] [Abstract][Full Text] [Related]
34. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
35. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
Peterson G
Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
[TBL] [Abstract][Full Text] [Related]
36. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
Monami M; Marchionni N; Mannucci E
Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
[TBL] [Abstract][Full Text] [Related]
37. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
38. Hyperplasia from GLP-1 drugs is "not a surprise," say researchers.
Cohen D
BMJ; 2013 Mar; 346():f2025. PubMed ID: 23535260
[No Abstract] [Full Text] [Related]
39. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.
Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S
J Clin Pharm Ther; 2014 Feb; 39(1):7-13. PubMed ID: 24127768
[TBL] [Abstract][Full Text] [Related]
40. Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes.
Wewer Albrechtsen NJ; Albrechtsen R; Bremholm L; Svendsen B; Kuhre RE; Poulsen SS; Christiansen CB; Jensen EP; Janus C; Hilsted L; Deacon CF; Hartmann B; Holst JJ
Cell Rep; 2016 Dec; 17(11):2845-2856. PubMed ID: 27974199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
